Ondine Biomedical Inc.

OBI · AIM · Health Care · mcap £55m · 9.7p

Beta Briefing, track record and signals & risks are not ready for Ondine Biomedical Inc. yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 20:35

All · 46 Key · 36

Date	Type	Announcement	Day
30 Sep 26		Capital Access Window - Ondine Biomedical Inc. COMMON SHARES OF NO PAR VALUE, FULLY PAID (CDI)	+0.0%
30 Sep 26		Capital Access Window Ondine announces equity fundraise under AIM Capital Access Window, trading paused.	+0.0%
30 Sep 26	Results	2026 Interim Results & Post-Period Momentum H1 2026 revenue up 23% to $1.25m; Phase 3 LANTERN trial met primary endpoint with 40.5% relative reduction in surgical site infection risk.	+0.0%
29 Sep 26		Ondine and Mela Advance NHS ICU Market Access Ondine partners with Mela Solutions to evaluate Steriwave nasal photodisinfection across NHS ICUs targeting 6-10 hospitals in year one.	+0.0%
23 Sep 26		Steriwave Deploys in 5 Southern Ontario Hospitals Five Southern Ontario hospitals to deploy Steriwave across approximately 5,000 annual surgical procedures.	+0.0%
10 Sep 26	Results	Investor Presentation of Phase 3 Topline Results Ondine Biomedical to Present Topline Results from Phase 3 LANTERN Trial	+2.3%
07 Sep 26		Largest Private Mexican Network Pilots Steriwave Mexico's largest private hospital network pilots Steriwave nasal photodisinfection at two flagship facilities on commercial basis.	+0.0%
04 Sep 26	Holding	Holding(s) in Company
03 Sep 26	Routine	Notification of major holdings - Pentwater
01 Sep 26	Results	Positive Topline Results in US Phase 3 Study Phase 3 LANTERN trial met primary endpoint with 40% relative reduction in surgical site infections versus standard care alone.	+2.1%
30 Jul 26		Major Scottish Hospital Adopts Steriwave NHS Golden Jubilee, Scotland's largest hip and knee replacement centre, adopts Steriwave nasal photodisinfection.	+0.0%
13 Jul 26		Update on US Phase 3 Pivotal Study LANTERN Phase 3 pivotal study topline results expected within approximately six weeks.	−6.9%
01 Jul 26		Keynote Address at 8th Annual Photodynamic Day Dr. Nicolas Loebel delivered keynote address at 8th Annual Photodynamic Day in Istanbul on Ondine's photodisinfection technology.	+2.7%
30 Jun 26	Results	Result of AGM and voting results
30 Jun 26		Leeds drops SSI 78% over Mupirocin with Steriwave Published Leeds study shows Steriwave reduced surgical site infections by 78% versus mupirocin in skull-base surgery.	+1.7%
22 Jun 26		Update on US Phase 3 Pivotal Study Phase 3 LANTERN study endpoint adjudication complete; top-line results expected within one to two weeks.	+1.7%
18 Jun 26		Leeds Drops SSIs by 78.5% in Complex Brain Surgery Ondine's nasal photodisinfection reduced surgical site infections by 78.5% in complex brain surgery at Leeds Teaching Hospitals.	+0.0%
08 Jun 26	Routine	Grant of Options and RSUs, and Issue of Warrants
04 Jun 26	Routine	Notice of AGM
04 Jun 26	Results	2025 Full Year Results and Annual Report 2025 revenue up 29% to $2.6m CAD; Phase 3 LANTERN trial patient enrolment completed with top-line results expected Spring 2026.	−3.4%
28 May 26	Routine	Notice of Results and Investor Presentation
26 May 26		Steriwave ICU Study Outcomes Presented at CSRT2026 SMURF feasibility study of nasal photodisinfection presented at CSRT2026 conference, showing exploratory reductions in pneumonia rates.	+0.0%
06 May 26	Routine	Notification of major holdings - hInsight-NX, LLC
06 May 26	Routine	Notification of major holdings - Carolyn Cross
05 May 26	Routine	Notification of major holdings - Pentwater
30 Apr 26		Ondine Presented Steriwave Data at IPC 2026 Ondine presented Steriwave nasal photodisinfection clinical data at IPC 2026 conference; product classified as NHS Innovation Product.	+0.0%
29 Apr 26	Fundraise	Result of Fundraise & TVR Ondine raised £5 million through placing and subscription at 12p per share, issuing 41.67 million new shares.	−6.0%
28 Apr 26	Fundraise	Proposed c.£5 million (C$9.23 million) Fundraise Ondine raises approximately £5 million via placing and subscription at 12 pence per share.	+0.0%
27 Apr 26		ICU Study to be Presented at 2026 CACCN Conference ICU study of Steriwave nasal photodisinfection accepted for oral presentation at Canadian Critical Care Nursing Conference.	+0.0%
23 Apr 26		Marked Reduction in SSIs at Ottawa Heart Institute University of Ottawa Heart Institute reports marked reduction in surgical site infections using Ondine's Steriwave nasal photodisinfection.	+4.2%
22 Apr 26		Two Abstracts Accepted at World Congress Two abstracts accepted for poster presentation at World Congress on Infectious Diseases in June 2026.	+4.3%
14 Apr 26		Steriwave ICU Study Shows 39.5% Pneumonia Drop Royal Columbian Hospital study shows Steriwave nasal photodisinfection reduces ICU pneumonia rates by 39.5%.	+2.3%
13 Apr 26		Business Update Completed LANTERN Phase 3 trial enrolment with 5,000 patients; 29% revenue growth in 2025; expanding manufacturing capacity.	+0.0%
08 Apr 26		ICU Study Accepted for Publication Pilot study of nasal photodisinfection in ICU setting accepted for publication in Journal of Critical Care.	+4.8%
10 Mar 26		Ondine Provides Update on US Phase 3 Pivotal Study LANTERN Phase 3 study 93% enrolled, on track for Spring 2026 top-line results.	+7.3%
03 Mar 26	Holding	Holding(s) in Company
25 Feb 26		Share Issuance for ICU Study Submission Ondine issues 1.18m shares at 9.75p following submission of ICU study results for publication.	+2.5%
06 Feb 26		Ondine and Mid Yorks Win National Award Ondine and Mid Yorkshire NHS Trust win national award for reducing surgical site infections using Steriwave technology.	+0.0%
02 Feb 26		Steriwave Up for 2025 “Product of the Year” Award Steriwave shortlisted as finalist for 2025 Bionow Product of the Year Award.	+0.0%
27 Jan 26		Expanding Steriwave Use Across Vancouver Island Cowichan District Hospital in British Columbia adopts Steriwave for orthopedic pre-surgical infection prevention.	+0.0%
22 Jan 26		Steriwave Expands into ENT Surgery in Spain Steriwave nasal photodisinfection technology deployed with leading ENT specialist group in Spain.	+3.1%
13 Jan 26		New Independent Study Supports Photodisinfection Independent study supports photodisinfection technology for nasal decolonization; separate evaluations report up to 70% reduction in surgical site infections.	+0.0%
23 Dec 25		Finalist for 2nd National Award for SSI reduction Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for national award for reducing surgical site infections using Steriwave nasal photodisinfection.	−4.4%
22 Dec 25		First German Hospital Pilots Steriwave Ondine announces research collaboration with LMU University Hospital Munich to pilot Steriwave photodisinfection in ENT patients.	−6.5%
16 Dec 25		Ondine shortlisted for HSJ Partnership Award Ondine shortlisted for HSJ Partnership Award for Steriwave nasal decolonisation technology reducing surgical infections.	−4.9%
27 Oct 25	Results	Topline Results Significant in Steriwave ICU Study Steriwave nasal photodisinfection achieved significant pathogen reduction in ICU pilot study at Royal Columbian Hospital.	+4.0%

Company filings. Not investment advice.